<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03425292</url>
  </required_header>
  <id_info>
    <org_study_id>JWCI-17-0801</org_study_id>
    <nct_id>NCT03425292</nct_id>
  </id_info>
  <brief_title>A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer</brief_title>
  <official_title>A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John Wayne Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>John Wayne Cancer Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety and tolerability of the research study drugs&#xD;
      nivolumab, ipilimumab, lomustine, bevacizumab, and temozolomide when used following surgery&#xD;
      and before standard therapy with radiation and temozolomide in patients with newly diagnosed&#xD;
      high grade glioma.&#xD;
&#xD;
      Additional aims of the study are to:&#xD;
&#xD;
        -  Find out side effects (good and bad) of study drug combinations.&#xD;
&#xD;
        -  Evaluate any preliminary evidence of anticancer activity of study drug combinations .&#xD;
&#xD;
        -  Evaluate tumor characteristics by collecting brain tumor tissue samples.&#xD;
&#xD;
        -  Measure the amount of nivolumab and ipilimumab in biospecimens.&#xD;
&#xD;
        -  Look at biomarkers in biospecimens.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients having a clinically planned surgical procedure (biopsy or cytoreduction) for a&#xD;
      suspected diagnosis of high grade glioma will be approached for participation in this study.&#xD;
      Tumor tissue obtained from surgery will be used for histological diagnosis and clinical&#xD;
      molecular profiling, and excess tumor tissue will be collected for potential correlative&#xD;
      studies. A small sample of blood and CSF for research will also be collected.&#xD;
&#xD;
      Once a diagnosis of high grade glioma is confirmed, the patient will be allocated to one of&#xD;
      the study arms. Treatment will be started approximately 7-42 days following surgery once the&#xD;
      patient has recovered from surgery. Routine clinical evaluations will be performed prior to&#xD;
      treatment initiation and throughout treatment as clinically indicated. Radiographic brain&#xD;
      imaging will be performed approximately 21-42 after treatment initiation and then routinely&#xD;
      for medical management. Tumor response will be assessed according to immunotherapy Response&#xD;
      Assessment in Neuro-Oncology (iRANO) Working Group criteria.&#xD;
&#xD;
      Treatment may continue until the patient experiences unacceptable toxicity or clear disease&#xD;
      progression. The determination of whether to stop treatment due to disease progression will&#xD;
      be based on the investigator's evaluation of the patient's clinical and radiographic&#xD;
      condition, taking into consideration the interpretation of localized inflammatory responses&#xD;
      that can mimic radiographic features of tumor progress. Patients discontinuing treatment will&#xD;
      have further medical management as directed by their treating physician.&#xD;
&#xD;
      As part of follow-up, if the patient undergoes a surgery, results of clinical molecular&#xD;
      profiling will be collected, and excess resected tumor tissue will be collected if available&#xD;
      along with blood and CSF for correlative studies. A record of any additional anti-cancer&#xD;
      treatments and survival status will be made every three to six months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of dose limiting toxicities</measure>
    <time_frame>first 28 days of treatment</time_frame>
    <description>treatment-related adverse events that impact administration of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-related adverse events</measure>
    <time_frame>approximately 7 months</time_frame>
    <description>Toxicity will be assessed according to the NCI Common Toxicity Criteria for Adverse Events (CTCAE), version 4.03.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response rates</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Evidence of anti-tumor activity as measured according to immunotherapy Response Assessment in Neuro-Oncology (iRANO) criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>The duration of time from start of treatment until objective tumor response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>The duration of time from start of treatment to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of immunotherapeutic agents in specimens</measure>
    <time_frame>approximately 4 months</time_frame>
    <description>Immunotherapeutic drug levels in specimens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in clinical molecular profile of tumor tissue after treatment</measure>
    <time_frame>approximately 6 months to 1 year</time_frame>
    <description>Comparison of tumor tissue molecular profile generated from before and after study treatment.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Newly Diagnosed High Grade Glioma</condition>
  <arm_group>
    <arm_group_label>1 SOC (closed to enrollment)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard conformal brain radiation therapy with concurrent and adjuvant temozolomide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 Nivo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 Nivo-Ipi (closed to enrollment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab plus Ipilimumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 Nivo-Ipi-CCNU-TMZ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab plus Ipilimumab plus Lomustine (CCNU) plus 5-day Temozolomide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 Nivo-Ipi-TMZ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab plus Ipilimumab plus metronomic Temozolomide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6 Nivo-Ipi-Bev-TMZ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab plus Ipilimumab plus Bevacizumab plus metronomic Temozolomide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>concomitant and 5-day adjuvant temozolomide</description>
    <arm_group_label>1 SOC (closed to enrollment)</arm_group_label>
    <other_name>temodar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>conformal brain radiation therapy</intervention_name>
    <description>standard radiation therapy for newly diagnosed glioblastoma</description>
    <arm_group_label>1 SOC (closed to enrollment)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>nivolumab 300 mg IV every 2 weeks</description>
    <arm_group_label>2 Nivo</arm_group_label>
    <arm_group_label>3 Nivo-Ipi (closed to enrollment)</arm_group_label>
    <arm_group_label>4 Nivo-Ipi-CCNU-TMZ</arm_group_label>
    <arm_group_label>5 Nivo-Ipi-TMZ</arm_group_label>
    <arm_group_label>6 Nivo-Ipi-Bev-TMZ</arm_group_label>
    <other_name>opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>ipilimumab 1 mg/kg IV every 6 weeks</description>
    <arm_group_label>3 Nivo-Ipi (closed to enrollment)</arm_group_label>
    <arm_group_label>4 Nivo-Ipi-CCNU-TMZ</arm_group_label>
    <arm_group_label>5 Nivo-Ipi-TMZ</arm_group_label>
    <arm_group_label>6 Nivo-Ipi-Bev-TMZ</arm_group_label>
    <other_name>yervoy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>bevacizumab 5 mg/kg IV every 2 weeks</description>
    <arm_group_label>6 Nivo-Ipi-Bev-TMZ</arm_group_label>
    <other_name>avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronomic Temozolomide</intervention_name>
    <description>50 mg/m^2 oral, once daily</description>
    <arm_group_label>5 Nivo-Ipi-TMZ</arm_group_label>
    <arm_group_label>6 Nivo-Ipi-Bev-TMZ</arm_group_label>
    <other_name>temodar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-day Temozolomide</intervention_name>
    <description>100 mg/m^2 oral, once daily on Days 2-6 of each 6 week course</description>
    <arm_group_label>4 Nivo-Ipi-CCNU-TMZ</arm_group_label>
    <other_name>temodar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lomustine</intervention_name>
    <description>100 mg/m^2 oral, on Day 1 of each 6 week course</description>
    <arm_group_label>4 Nivo-Ipi-CCNU-TMZ</arm_group_label>
    <other_name>CCNU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participant has the ability to understand and the willingness to provide a signed and&#xD;
             dated informed consent form.&#xD;
&#xD;
          2. Participant has the willingness to comply with all study procedures and availability&#xD;
             for the duration of the study.&#xD;
&#xD;
          3. Participant is being evaluated for a potential, or known, diagnosis of high grade&#xD;
             glioma.&#xD;
&#xD;
          4. Participant is a candidate for brain surgery or has undergone prior surgery and has&#xD;
             not received any additional treatment for high grade glioma.&#xD;
&#xD;
          5. Participant is male or female, ≥ 18 years of age.&#xD;
&#xD;
          6. Participant has a Karnofsky Performance Status (KPS) ≥ 60%:&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participant has received prior anti-cancer treatment for high grade glioma.&#xD;
&#xD;
          2. Participant has a diagnosis of immunodeficiency or active autoimmune disease.&#xD;
&#xD;
          3. Participant is receiving chronic systemic steroid therapy in dosing exceeding 8 mg&#xD;
             daily of dexamethasone equivalent or any other form of immunosuppressive therapy&#xD;
             within 7 days prior to the first dose of study drug. Note: This is assessed after&#xD;
             surgery, prior to starting drug treatment.&#xD;
&#xD;
          4. Participant has received a live vaccine within 28 days prior to the first dose of&#xD;
             study agent. Examples of live vaccines include, but are not limited to measles, mumps,&#xD;
             rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus&#xD;
             Calmette-Guérin (BCG), typhoid vaccine, and intranasal influenza vaccines (e.g.,&#xD;
             FluMist®).&#xD;
&#xD;
          5. Participant has a severe or uncontrolled medical disorder that would, in the&#xD;
             investigator's opinion, impair ability to receive study intervention (i.e.,&#xD;
             uncontrolled diabetes, chronic renal disease, chronic pulmonary disease or active,&#xD;
             uncontrolled infection, psychiatric illness/social situations that would limit&#xD;
             compliance with study requirements).&#xD;
&#xD;
          6. Participant is a female of childbearing potential who is pregnant or nursing.&#xD;
&#xD;
          7. Participant has a history of thrombotic or hemorrhagic stroke or myocardial infarction&#xD;
             within 6 months.&#xD;
&#xD;
          8. Participant has a history of intestinal perforations, fistula, hemorrhages, and/or&#xD;
             hemoptysis ≤ 6 months prior to first study treatment.&#xD;
&#xD;
          9. Participant has active gastrointestinal bleeding.&#xD;
&#xD;
         10. Participant has uncontrolled hypertension (systolic blood pressure ≥ 160 mm Hg and/or&#xD;
             diastolic blood pressure ≥ 90 mm Hg).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Santosh Kesari, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>John Wayne Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Team</last_name>
    <phone>310-829-8265</phone>
    <email>neuro.oncology@jwci.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>John Wayne Cancer Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trial Team</last_name>
      <phone>310-829-8265</phone>
      <email>neuro.oncology@jwci.org</email>
    </contact>
    <investigator>
      <last_name>Santosh Kesari, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 21, 2018</study_first_submitted>
  <study_first_submitted_qc>February 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2018</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>John Wayne Cancer Institute</investigator_affiliation>
    <investigator_full_name>Santosh Kesari</investigator_full_name>
    <investigator_title>Professor, Neurosciences</investigator_title>
  </responsible_party>
  <keyword>immunotherapy</keyword>
  <keyword>nivolumab</keyword>
  <keyword>ipilimumab</keyword>
  <keyword>bevcizumab</keyword>
  <keyword>temozolomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Lomustine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

